News | August 13, 2025
Marksans Pharma reports Q1 FY26 gross profit 8.9% higher at Rs. 358.2 Cr
EBITDA stood at Rs. 100.1 crore with a margin of 16.1 per cent
EBITDA stood at Rs. 100.1 crore with a margin of 16.1 per cent
The company reported revenue from operations at Rs. 6,573.7 crore, up 6 per cent YoY
Under an exclusive distribution agreement, Sartorius Stedim Biotech will offer Nanotein’s lead products globally
Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment that binds to and inhibits vascular endothelial growth factor A
Dr. Venkatraman brings over 25 years of experience in small molecule and Biologics drug development, manufacturing, and advancing strategic growth initiatives
Aurobindo Pharma’s US formulations revenue slipped 1.9% on a year-on-year basis to Rs. 3,488 crore
Cupid reported total income of Rs. 64.75 crore in Q1 FY26 as compared to Rs. 44.03 crore in Q1 Fy25
Hikal has reported total income of Rs. 381.4 crores during the period ended June 30, 2025
IOLCP has reported total income of Rs. 559.06 crores during the period ended June 30, 2025
Tamsulosin, an alpha-1 adrenergic receptor blocker, combined with Dutasteride, a dual 5- alpha-reductase inhibitor, is indicated for the treatment of moderate to severe symptoms of benign prostatic hyperplasia (BPH) in adult men
Subscribe To Our Newsletter & Stay Updated
